The invention relates to anilinopyrimidine compound crystals used as EGFR inhibitors, belonging to the field of medical chemistry. Specifically, the invention relates to crystals of N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide (as shown in a formula I which is described in the specification) hydrochloride; and the invention also relates to preparation methods for the crystals, crystal compositions containing the crystals, pharmaceutical compositions containing the crystals or the crystal compositions thereof, and pharmaceutical application of the crystals, the crystal compositions and the pharmaceutical compositions. The crystals provided by the invention have the advantages of high purity, high crystallinity, good stability, etc.